Last reviewed · How we verify

Ma Fei，MD — Portfolio Competitive Intelligence Brief

Ma Fei，MD pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Eribulin biweekly regimen Eribulin biweekly regimen phase 3 Microtubule inhibitor Tubulin / Microtubules Oncology
Eribulin standard regimen Eribulin standard regimen phase 3 Microtubule inhibitor Tubulin (microtubule dynamics) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Eisai Co., Ltd. · 1 shared drug class
  2. Jiangsu Alphamab Biopharmaceuticals Co., Ltd · 1 shared drug class
  3. Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
  4. Nippon Kayaku Co., Ltd. · 1 shared drug class
  5. Shanghai Hengrui Pharmaceutical Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ma Fei，MD:

Cite this brief

Drug Landscape (2026). Ma Fei，MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ma-fei-md. Accessed 2026-05-15.

Related